{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:19:50Z","timestamp":1783423190672,"version":"3.54.6"},"reference-count":41,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400462"],"award-info":[{"award-number":["82400462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background:High-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP), has increasingly been implicated in the pathogenesis of various cardiovascular diseases. This study aimed to elucidate the relationship between circulating HMGB1 levels and the development of heart failure (HF).Methods:This single-center cross-sectional study enrolled 412 patients presenting with chest tightness or pain at the Department of Cardiovascular Medicine, First Affiliated Hospital of Nanchang University, between January and July 2025. The relationship between HMGB1 and HF occurrence was evaluated using Spearman\u2019s correlation analysis, logistic regression models, restricted cubic spline (RCS) plots, and receiver operating characteristic (ROC) curves. Subgroup analyses were also performed to assess the robustness of the findings.Results:Of the 412 enrolled patients, 343 were included in the final analysis after application of the exclusion criteria; 151 were diagnosed with HF, and 192 served as controls. Serum HMGB1 levels were significantly higher in the HF group than in the control group (1.53 ng\/mL vs 0.93 ng\/mL; p &lt; 0.001). Spearman's correlation analysis revealed significant positive correlations between HMGB1 levels and left ventricular end-diastolic diameter (LVEDD), left atrial diameter (LAD), and the systemic inflammatory response index (SIRI), and a significant negative correlation with left ventricular ejection fraction (LVEF) (all p &lt; 0.05). In the univariate logistic regression analysis, elevated HMGB1 levels were strongly associated with increased HF risk (odds ratio [OR] = 2.942, 95% confidence interval [CI]: 2.113\u20134.095; p &lt; 0.001). This association remained significant in multivariable models after sequential adjustment for demographic, clinical, and laboratory covariates, with a fully adjusted OR of 2.273 (95% CI: 1.410\u20133.663; p &lt; 0.001). Restricted cubic spline (RCS) analysis confirmed a linear dose\u2013response relationship between HMGB1 levels and HF risk (p for nonlinearity = 0.174). ROC analysis showed that HMGB1 alone had good predictive value for HF (area under the curve [AUC] = 0.736), outperforming individual traditional markers. Furthermore, a combined model incorporating HMGB1, LVEF, LVEDD, LAD, and SIRI achieved superior predictive accuracy (AUC = 0.807). Finally, subgroup analyses showed that only sex exhibited a significant interaction, while interactions for all other variables were non significant interaction ( p for interaction &gt; 0.05), indicating that this relationship was robust and independent of major clinical variables.Conclusions:The levels of HMGB1 elevation were significantly related to the occurrence of HF, which may serve as a potential biomarker for the development of innovative therapeutic strategies in patients with heart failure.<\/jats:p>","DOI":"10.31083\/rcm49717","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:15Z","timestamp":1783422375000},"source":"Crossref","is-referenced-by-count":0,"title":["Elevated Circulating HMGB1 Levels as a Potential Biomarker for the Diagnosis and Therapy of Heart Failure: A Cross-Sectional Study"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9045-519X","authenticated-orcid":true,"given":"Xiaoting","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"},{"name":"Academician Workstation of Cardiovascular Innovative Materials, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Hypertension Research Institute, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7146-1236","authenticated-orcid":true,"given":"Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0050-5490","authenticated-orcid":true,"given":"Shaolin","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"},{"name":"Academician Workstation of Cardiovascular Innovative Materials, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Hypertension Research Institute, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-3346","authenticated-orcid":true,"given":"Xiaoping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"},{"name":"Academician Workstation of Cardiovascular Innovative Materials, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Hypertension Research Institute, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-4155","authenticated-orcid":true,"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China"},{"name":"Academician Workstation of Cardiovascular Innovative Materials, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Hypertension Research Institute, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature Reviews. Cardiology. 2016; 13: 368\u2013378.","DOI":"10.1038\/nrcardio.2016.25"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology. 2014; 63: 1123\u20131133.","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al. Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study. Journal of the American Heart Association. 2023; 12: e027852.","DOI":"10.1161\/JAHA.122.027852"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015. European Journal of Heart Failure. 2019; 21: 1329\u20131337.","DOI":"10.1002\/ejhf.1629"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Peng X, Wang J, Li J, Li Y, Wang X, Liu X, et al. Gender-specific prevalence and trend of heart failure in China from 1990 to 2019. ESC Heart Failure. 2023; 10: 1883\u20131895.","DOI":"10.1002\/ehf2.14361"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Poelzl G, Fetz B, Altenberger J, Fritsch M, Auer J, Stachl E, et al. Heart failure disease management programs in Austria 2019 : A systematic survey of the Heart Failure Working Group and the Working Group for Cardiological Assistance and Care Personnel of the Austrian Society of Cardiology. Wiener Klinische Wochenschrift. 2020; 132: 310\u2013321.","DOI":"10.1007\/s00508-020-01615-y"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ravassa S, L\u00f3pez B, Treibel TA, San Jos\u00e9 G, Losada-Fuentenebro B, Tapia L, et al. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies. Molecular Aspects of Medicine. 2023; 93: 101194.","DOI":"10.1016\/j.mam.2023.101194"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020; 75: 1324\u20131340.","DOI":"10.1016\/j.jacc.2020.01.014"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Alogna A, Koepp KE, Sabbah M, Espindola Netto JM, Jensen MD, Kirkland JL, et al. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction. JACC. Heart Failure. 2023; 11: 1549\u20131561.","DOI":"10.1016\/j.jchf.2023.06.031"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Amara M, Stoler O, Birati EY. The Role of Inflammation in the Pathophysiology of Heart Failure. Cells. 2025; 14: 1117.","DOI":"10.3390\/cells14141117"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock (Augusta, Ga.). 2001; 15: 247\u2013253.","DOI":"10.1097\/00024382-200115040-00001"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Experimental & Molecular Medicine. 2022; 54: 91\u2013102.","DOI":"10.1038\/s12276-022-00736-w"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nature Reviews. Immunology. 2023; 23: 824\u2013841.","DOI":"10.1038\/s41577-023-00894-6"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Volz HC, Laohachewin D, Schellberg D, Wienbrandt AR, Nelles M, Zugck C, et al. HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clinical Research in Cardiology : Official Journal of the German Cardiac Society. 2012; 101: 427\u2013435.","DOI":"10.1007\/s00392-011-0409-x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Zhang L, Liu M, Jiang H, Yu Y, Yu P, Tong R, et al. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure. Journal of Cellular and Molecular Medicine. 2016; 20: 459\u2013470.","DOI":"10.1111\/jcmm.12743"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hay\u0131ro\u011flu M\u0130, \u00c7\u0131nar T, \u00c7inier G, Pay L, Yumurta\u015f A\u00c7, Tezen O, et al. Evaluating systemic immune-inflammation index in patients with implantable cardioverter defibrillator for heart failure with reduced ejection fraction. Pacing and Clinical Electrophysiology : PACE. 2022; 45: 188\u2013195.","DOI":"10.1111\/pace.14436"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009; 119: 3070\u20133077.","DOI":"10.1161\/CIRCULATIONAHA.108.815944"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Paulus WJ, Zile MR. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. Circulation Research. 2021; 128: 1451\u20131467.","DOI":"10.1161\/CIRCRESAHA.121.318159"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lafuse WP, Wozniak DJ, Rajaram MVS. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells. 2020; 10: 51.","DOI":"10.3390\/cells10010051"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Pay L, Yumurta\u015f A\u00c7, Tezen O, \u00c7etin T, Eren S, \u00c7\u0131nar T, et al. Prognostic value of serum albumin in heart failure patients with cardiac resynchronization therapy. Biomarkers in Medicine. 2024; 18: 363\u2013371.","DOI":"10.1080\/17520363.2024.2347200"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"\u00c7inier G, Hay\u0131ro\u011flu M\u0130, Pay L, Yumurta\u015f A\u00c7, Tezen O, Eren S, et al. Prognostic nutritional index as the predictor of long-term mortality among HFrEF patients with ICD. Pacing and Clinical Electrophysiology : PACE. 2021; 44: 490\u2013496.","DOI":"10.1111\/pace.14170"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"\u00c7inier G, Hay\u0131ro\u011flu M\u0130, Kolak Z, Tezen O, Yumurta\u015f A\u00c7, Pay L, et al. The value of C-reactive protein-to-albumin ratio in predicting long-term mortality among HFrEF patients with implantable cardiac defibrillators. European Journal of Clinical Investigation. 2021; 51: e13550.","DOI":"10.1111\/eci.13550"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, et al. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. International Journal of Biological Sciences. 2023; 19: 5020\u20135035.","DOI":"10.7150\/ijbs.87964"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Peng R, Zuo S, Li X, Huang Y, Chen S, Zou X, et al. Investigating HMGB1 as a potential serum biomarker for early diabetic nephropathy monitoring by quantitative proteomics. iscience. 2024; 27: 108834.","DOI":"10.1016\/j.isci.2024.108834"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, et al. Elevated serum levels of S100A8\/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular & Molecular Immunology. 2020; 17: 992\u2013994.","DOI":"10.1038\/s41423-020-0492-x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Hashimoto T, Ishii J, Kitagawa F, Yamada S, Hattori K, Okumura M, et al. Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2012; 221: 490\u2013495.","DOI":"10.1016\/j.atherosclerosis.2012.01.040"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wahid A, Wen J, Yang Q, Zhang Z, Zhao X, Tang X. Serum HMGB1 is a biomarker for acute myocardial infarction with or without heart failure. Clinical and Translational Science. 2023; 16: 2299\u20132309.","DOI":"10.1111\/cts.13630"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Liu T, Zhang DY, Zhou YH, Han QF, Wang LH, Wu L, et al. Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure. International Journal of Cardiology. 2015; 184: 318\u2013320.","DOI":"10.1016\/j.ijcard.2015.02.088"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Lu H, Zhang Z, Barnie PA, Su Z. Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury. Cytokine & Growth Factor Reviews. 2019; 47: 74\u201382.","DOI":"10.1016\/j.cytogfr.2019.05.009"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Van Linthout S, Tsch\u00f6pe C. Inflammation - Cause or Consequence of Heart Failure or Both? Current Heart Failure Reports. 2017; 14: 251\u2013265.","DOI":"10.1007\/s11897-017-0337-9"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, et al. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC. Heart Failure. 2024; 12: 451\u2013460.","DOI":"10.1016\/j.jchf.2023.11.005"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opinion on Therapeutic Targets. 2018; 22: 263\u2013277.","DOI":"10.1080\/14728222.2018.1439924"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Asta L, Pisano C, Sbrigata A, Raffa GM, Scola L, Balistreri CR. Biomarkers in Heart Failure: A Review and a Wish. International Journal of Molecular Sciences. 2025; 26: 8046.","DOI":"10.3390\/ijms26168046"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Journal of Cardiac Failure. 2023; 29: 787\u2013804.","DOI":"10.1016\/j.cardfail.2023.02.009"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, et al. Clinical Implications of the New York Heart Association Classification. Journal of the American Heart Association. 2019; 8: e014240.","DOI":"10.1161\/JAHA.119.014240"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduction and Targeted Therapy. 2023; 8: 239.","DOI":"10.1038\/s41392-023-01502-8"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Andonian BJ, Hippensteel JA, Abuabara K, Boyle EM, Colbert JF, Devinney MJ, et al. Inflammation and aging-related disease: A transdisciplinary inflammaging framework. GeroScience. 2025; 47: 515\u2013542.","DOI":"10.1007\/s11357-024-01364-0"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Jin X, Rong S, Yuan W, Gu L, Jia J, Wang L, et al. High Mobility Group Box 1 Promotes Aortic Calcification in Chronic Kidney Disease via the Wnt\/\u03b2-Catenin Pathway. Frontiers in Physiology. 2018; 9: 665.","DOI":"10.3389\/fphys.2018.00665"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Wang L, Yi J, Wang W, Zhou Z, Liu J, Zhang H, et al. Impact of first-line antihypertensive drug class and intensity on NT-proBNP improvement and cardiovascular outcomes among hypertensive patients with pre-heart failure: findings from SPRINT trial. Hypertension Research : Official Journal of the Japanese Society of Hypertension. 2024; 47: 3447\u20133457.","DOI":"10.1038\/s41440-024-01873-7"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Cicek V, Babaoglu M, Saylik F, Yavuz S, Mazlum AF, Genc MS, et al. A New Risk Prediction Model for the Assessment of Myocardial Injury in Elderly Patients Undergoing Non-Elective Surgery. Journal of Cardiovascular Development and Disease. 2024; 12: 6.","DOI":"10.3390\/jcdd12010006"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM49717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:09:50Z","timestamp":1783422590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM49717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02295-7"],"URL":"https:\/\/doi.org\/10.31083\/rcm49717","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"49717"}}